Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream

Inclusion criteria

• Patients older than 18 years of age, of either sex;
• Patients diagnosed with mild-to-moderate psoriasis (PASI and BSA <10) requiring monotherapy topical with Wynzora;
• Patients who have stopped treatment with Enstilar foam for any reason for at least 30 days; and
• Patients whose medical records are accessible and record all demographic parameters, anthropometric and clinical parameters during the treatment period
• Signature of written informed consent;

Exclusion criteria

• Patients with palmoplantar, inverse, erythrodermic, guttate, and scalp psoriasis.
• Patients who are taking concomitant systemic therapies for psoriasis, such as. cyclosporine, methotrexate, acitretin, phototherapy or biologic therapies.
• Women who are pregnant or planning to become pregnant.
• Patients with disabilities or other motor problems that could complicate self-medication.